Postoperative stimulated thyroglobulin and the ps-tg/TSH ratio enhance the 2025 ATA risk stratification for predicting radioiodine response in papillary thyroid carcinoma.
The study suggests that combining postoperative stimulated thyroglobulin and the ps-Tg/TSH ratio may improve risk stratification for patients with papillary thyroid carcinoma after radioactive iodine therapy.
Where it sits
this study against the rest of the hcg (human chorionic gonadotropin) corpusSummary and findings
This study evaluated the predictive value of postoperative stimulated thyroglobulin (ps-Tg) and the ps-Tg/TSH ratio in assessing treatment response in papillary thyroid carcinoma (PTC) patients after radioactive iodine therapy. A total of 1,117 patients were analyzed, and two models were compared to estimate the probability of achieving an excellent response one year post-therapy. The study found that the combined model incorporating multiple factors outperformed a simpler model.
Abstract
Background Postoperative stimulated thyroglobulin (ps-Tg) is an established biomarker for assessing treatment response in papillary thyroid carcinoma (PTC), but optimal integration of biochemical parameters into the 2025 American Thyroid Association (ATA) recurrence risk stratification system remains undefined. Materials and methods We retrospectively analyzed 1,117 PTC patients who underwent first radioactive iodine (RAI) therapy at the First Affiliated Hospital of Jinan University between 2015 and 2021. Two models were built to estimate the probability of achieving an excellent response (ER) 1 year after RAI: Model 1 included all variables selected by LASSO (pathological N stage, 2025 ATA recurrence risk stratification, ps-Tg, ps-Tg/thyroid-stimulating hormone [TSH] ratio, and thyroglobulin antibody [TgAb]); Model 2 served as a control, including only pathological N stage and recurrence risk stratification. Model performance was evaluated using receiver operating characteristic (ROC) analysis, LASSO regression, decision curve analysis (DCA), and net reclassification improvement (NRI). Results ROC analysis identified optimal cut-off values of 4.10 ng/mL for ps-Tg and 0.07 for the ps-Tg/TSH ratio (area under the curve [AUC] 0.856 and 0.843, respectively). In the training cohort, Model 1 outperformed Model 2 (AUC 0.862 vs. 0.614; R2 0.531 vs. 0.056) and significantly improved reclassification (IDI 0.389; overall NRI 0.297; event NRI 0.163). DCA demonstrated greater clinical net benefit for Model 1 across risk thresholds of 0.02-0.80, and findings in the validation cohort were consistent. Conclusion Based on ps-Tg, the ps-Tg/TSH ratio, TgAb, pathological N stage, and the ATA 2025 recurrence risk stratification, the combined model showed good predictive value for 1-year ER after RAI therapy in patients with PTC. This model may serve as a complementary tool to existing postoperative risk assessment and provide additional support for follow-up stratification and individualized management.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.